Clinical trial
The Effect of the Selective PDE5 Inhibitor, Sildenafil, on Aura and Migraine Headache Induction.
NCT02795351 is registered in ClinicalTrials.gov with Herlev Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Effect of the Selective PDE5 Inhibitor, Sildenafil, on Aura and Migraine Headache Induction.
- Lead sponsor
- Herlev Hospital
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 30, 2015
- Completion date
- August 31, 2021
- Enrollment
- 16 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.